semaglutide glp-1 ra Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects GLP-1 physiology in obesity and

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and during pregnancy or breastfeeding

Superko HR, Zhao XQ, Hodis HN, Guyton JR

10.2337/dc10-2415 [DOI] [PMC free article] [PubMed] [Google Scholar] 35

Pricing Disclaimer: All prices mentioned were accurate at the time of publication (January 2026) but are subject to change

Since retatrutide is still in clinical development , long-term nutritional data is limited compared to semaglutide and tirzepatide

GLP-1 medications provide significant heart protection by reducing inflammation, improving cholesterol profiles, and lowering the risk of heart failure and stroke